Duolingo Inc vs uniQure N.V. Ordinary Shares — how do they compare? Duolingo Inc trades at $138.19 (market cap $6.54B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: Duolingo Inc is far larger — about 4.5× uniQure N.V. Ordinary Shares's market cap, and Duolingo Inc is more actively traded (985,128 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 138 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| DUOL | QURE | |
|---|---|---|
Market Cap | $6.54B | $1.45B |
Volume | 985,128 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $341.08 | $70.59 |
52-Week Low | $90.03 | $9.03 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $5.31B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $140.1, down 5.17% over the past day, amid mixed technical signals but strong fundamental performance. The stock shows a bullish moving average trend and neutral oscillators, with key support near $143. Financially, the company reported robust revenue growth, reaching $1.04 billion in 2025, with a net income margin of 35.87% and consistent earnings beats in recent quarters. Recent news highlights CEO share sales and AI-driven growth initiatives, contributing to investor attention.
The outlook for DUOL remains positive given its earnings momentum and expanding user base, though risks include insider selling and competitive pressures. Analyst consensus leans bullish with a $142.50 price target, suggesting modest upside from current levels, supported by institutional interest and solid cash flow generation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →